406 related articles for article (PubMed ID: 18568671)
41. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
[No Abstract] [Full Text] [Related]
42. Epidermoid carcinoma of the lip: an immunohistochemical study.
García-Montesinos-Perea B; Val-Bernal JF; Saiz-Bustillo R
Med Oral Patol Oral Cir Bucal; 2005; 10(5):454-61. PubMed ID: 16264381
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of biomarkers in breast and prostate cancer.
Grizzle WE; Myers RB; Arnold MM; Srivastava S
J Cell Biochem Suppl; 1994; 19():259-66. PubMed ID: 7823598
[TBL] [Abstract][Full Text] [Related]
44. Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer.
Hainsworth PJ; Henderson MA; Stillwell RG; Bennett RC
Eur J Surg Oncol; 1991 Feb; 17(1):9-15. PubMed ID: 1671658
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
46. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.
Hagel C; Krog B; Laas R; Stavrou DK
J Exp Clin Cancer Res; 1999 Sep; 18(3):305-9. PubMed ID: 10606174
[TBL] [Abstract][Full Text] [Related]
47. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
48. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
Selim AG; El-Ayat G; Wells CA
Virchows Arch; 2002 Nov; 441(5):449-55. PubMed ID: 12447674
[TBL] [Abstract][Full Text] [Related]
49. Expression of p53 protein in infiltrating and in-situ breast carcinomas.
Walker RA; Dearing SJ; Lane DP; Varley JM
J Pathol; 1991 Nov; 165(3):203-11. PubMed ID: 1684809
[TBL] [Abstract][Full Text] [Related]
50. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.
Kajiwara Y; Yamasaki F; Hama S; Yahara K; Yoshioka H; Sugiyama K; Arita K; Kurisu K
Cancer; 2003 Feb; 97(4):1077-83. PubMed ID: 12569609
[TBL] [Abstract][Full Text] [Related]
51. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.
Linke SP; Bremer TM; Herold CD; Sauter G; Diamond C
Clin Cancer Res; 2006 Feb; 12(4):1175-83. PubMed ID: 16489071
[TBL] [Abstract][Full Text] [Related]
52. Angiogenesis and p53 at the invading tumor edge: prognostic markers for colorectal cancer beyond stage.
Georgiou L; Minopoulos G; Lirantzopoulos N; Fiska-Demetriou A; Maltezos E; Sivridis E
J Surg Res; 2006 Mar; 131(1):118-23. PubMed ID: 16325858
[TBL] [Abstract][Full Text] [Related]
53. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
Sirotkovic-Skerlev M; Krizanac S; Kapitanovic S; Husnjak K; Unusic J; Pavelic K
Exp Mol Pathol; 2005 Aug; 79(1):42-50. PubMed ID: 16005711
[TBL] [Abstract][Full Text] [Related]
54. Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor?
Jacobs TW; Siziopikou KP; Prioleau JE; Raza S; Baum JK; Hayes DF; Schnitt SJ
Mod Pathol; 1998 Mar; 11(3):259-64. PubMed ID: 9521472
[TBL] [Abstract][Full Text] [Related]
55. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm.
Pich A; Margaria E; Chiusa L; Bortolin P; Palestro G
Oncol Rep; 2003; 10(5):1329-35. PubMed ID: 12883702
[TBL] [Abstract][Full Text] [Related]
56. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast.
Park SS; Kim JE; Kim YA; Kim YC; Kim SW
Histopathology; 2005 Dec; 47(6):625-30. PubMed ID: 16324201
[TBL] [Abstract][Full Text] [Related]
57. Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer.
Demirbaş S; Sücüllü I; Yildirim S; Celenk T
Turk J Gastroenterol; 2006 Mar; 17(1):13-9. PubMed ID: 16830272
[TBL] [Abstract][Full Text] [Related]
58. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.
Moreno A; Lloveras B; Figueras A; Escobedo A; Ramon JM; Sierra A; Fabra A
Mod Pathol; 1997 Nov; 10(11):1088-92. PubMed ID: 9388058
[TBL] [Abstract][Full Text] [Related]
59. Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma.
Sebastiani V; Botti C; Di Tondo U; Visca P; Pizzuti L; Santeusanio G; Alo PL
Anticancer Res; 2006; 26(4B):2983-7. PubMed ID: 16886624
[TBL] [Abstract][Full Text] [Related]
60. Male breast cancer: pathological and immunohistochemical features.
Willsher PC; Leach IH; Ellis IO; Bell JA; Elston CW; Bourke JB; Blamey RW; Robertson JF
Anticancer Res; 1997; 17(3C):2335-8. PubMed ID: 9245247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
